$2.52
1.37% today
Nasdaq, Apr 04, 09:19 pm CET
ISIN
US3596161097
Symbol
FULC
Sector
Industry

Fulcrum Therapeutics Inc Stock price

$2.55
-0.69 21.30% 1M
-1.12 30.42% 6M
-2.15 45.74% YTD
-6.58 72.07% 1Y
-21.45 89.38% 3Y
-6.56 72.01% 5Y
-10.95 81.11% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.28 9.89%
ISIN
US3596161097
Symbol
FULC
Sector
Industry

Key metrics

Market capitalization $137.65m
Enterprise Value $-94.74m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 37.90
EV/Sales (TTM) EV/Sales -1.18
P/S ratio (TTM) P/S ratio 1.72
P/B ratio (TTM) P/B ratio 0.57
Revenue growth (TTM) Revenue growth 2,752.05%
Revenue (TTM) Revenue $80.00m
EBIT (operating result TTM) EBIT $-19.83m
Free Cash Flow (TTM) Free Cash Flow $-2.50m
Cash position $241.02m
EPS (TTM) EPS $-0.22
P/E forward negative
Short interest 12.52%
Show more

Is Fulcrum Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Fulcrum Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Fulcrum Therapeutics Inc forecast:

2x Buy
29%
4x Hold
57%
1x Sell
14%

Analyst Opinions

7 Analysts have issued a Fulcrum Therapeutics Inc forecast:

Buy
29%
Hold
57%
Sell
14%

Financial data from Fulcrum Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
80 80
2,747% 2,747%
100%
- Direct Costs 1.65 1.65
24% 24%
2%
78 78
12,337% 12,337%
98%
- Selling and Administrative Expenses 35 35
11% 11%
44%
- Research and Development Expense 62 62
12% 12%
77%
-18 -18
83% 83%
-23%
- Depreciation and Amortization 1.65 1.65
24% 24%
2%
EBIT (Operating Income) EBIT -20 -20
82% 82%
-25%
Net Profit -9.73 -9.73
90% 90%
-12%

In millions USD.

Don't miss a Thing! We will send you all news about Fulcrum Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fulcrum Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about one month ago
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami,...
Neutral
Seeking Alpha
about one month ago
Fulcrum Therapeutics, Inc. (FULC) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
about one month ago
― On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose cohort by the end of 2025 ―
More Fulcrum Therapeutics Inc News

Company Profile

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Alexander Sapir
Employees 45
Founded 2015
Website www.fulcrumtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today